Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DJR8 | ISIN: US05337M1045 | Ticker-Symbol: AWK1
Tradegate
28.03.24
09:24 Uhr
15,800 Euro
+0,200
+1,28 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
AVADEL PHARMACEUTICALS PLC ADR Chart 1 Jahr
5-Tage-Chart
AVADEL PHARMACEUTICALS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
15,70015,80020:33
15,70015,80020:32

Aktuelle News zur AVADEL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.03.Avadel shares rise as Oppenheimer lifts price target to $292
05.03.Avadel shares rise as Craig-Hallum lifts price target to $222
05.03.Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript1
05.03.Avadel Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results4
04.03.Earnings call: Avadel Pharmaceuticals reports strong growth in 20233
04.03.Avadel wins patent suit, plans appeal on another2
04.03.Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Issues Statement On Patent Litigation159DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District...
► Artikel lesen
04.03.Avadel drops after jury rules in favor of Jazz Pharmaceuticals in patent dispute8
04.03.US STOCKS Avidity, C4 Therapeutics, Avadel Pharma2
04.03.Avadel Pharma rises on strong demand for sleep disorder drug1
04.03.Avadel Pharmaceuticals GAAP EPS of -$0.32 misses by $0.07, revenue of $19.5M misses by $6.2M4
04.03.Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results254-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ -- -- As of January 31st, greater than 2,200 patients enrolled in RYZUPTM and...
► Artikel lesen
04.03.AVADEL PHARMACEUTICALS PLC - 8-K, Current Report1
01.03.Avadel Pharmaceuticals Q4 2023 Earnings Preview8
01.03.Avadel Pharmaceuticals PLC reports results for the quarter ended in December - Earnings Summary6
29.02.AVADEL PHARMACEUTICALS PLC - 10-K, Annual Report3
06.02.UBS sets $21 target on Avadel, bullish on Lumryz launch2
18.01.Here's Why You Should Invest in Avadel (AVDL) Stock Now3
08.01.Avadel Pharmaceuticals estimates Q4 net product revenue of ~$19M5
08.01.Avadel climbs on upbeat Q4 2023 prelim revenue3
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1